TriSalus Life Sciences, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
TLSI Nasdaq 2834 trisaluslifesci.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for TriSalus Life Sciences, Inc.

TriSalus Life Sciences® Announces That Its Researchers Received Two JVIR Top Paper Awards for the Publication of "Intra-arterial Pressure-Enabled Drug Delivery™ Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model" - Mar 6th, 2025 1:00 pm
TriSalus Life Sciences Announces Key Appointments to Board of Directors - Feb 3rd, 2025 9:05 pm
TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed - Feb 3rd, 2025 1:00 pm
TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call - Jan 23rd, 2025 1:00 pm
TriSalus Life Sciences announces publication of pre-clinical data - Jan 10th, 2025 1:30 pm
TriSalus Life Sciences® Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres® to Liver Tumors using Pressure-Enabled Drug Delivery™ (PEDD™) via the TriNav® Infusion System - Jan 9th, 2025 1:00 pm
TriSalus Announces Leadership Changes - Jan 8th, 2025 1:00 pm
TriSalus Reports Q3 2024 Financial Results and Provides Business Update - Nov 14th, 2024 1:00 pm
TriSalus Life Sciences® Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav® Infusion System to U.S. Veterans with Liver Cancer - Nov 11th, 2024 12:00 pm
TriSalus Life Sciences Launches TriNav® LV Infusion System and TriGuide™ Guiding Catheters, Expanding Portfolio of PEDD™ Devices for Improved Tumor Treatment - Nov 7th, 2024 12:00 pm
TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call - Oct 31st, 2024 12:00 pm
TriSalus Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit - Oct 14th, 2024 8:05 pm
TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board - Sep 26th, 2024 11:00 am
TriSalus Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With PEDD™ Method via the TriNav® Infusion System - Sep 23rd, 2024 11:00 am
TriSalus Life Sciences Inc (TLSI) CEO Buys Shares - Sep 14th, 2024 5:52 am
TriSalus Reports Q2 2024 Financial Results and Business Update - Aug 15th, 2024 12:00 pm
TriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference Call - Aug 1st, 2024 11:00 am
TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation - Jul 1st, 2024 8:00 pm
TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants - Jun 26th, 2024 9:45 pm
TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting - Jun 3rd, 2024 11:00 am